Core Insights - Aadi Bioscience, Inc. announced new nonclinical data showing that nab-sirolimus has significantly higher intratumoral drug concentration, stronger inhibition of mTOR targets, and greater antitumor activity compared to intravenous and oral mTOR inhibitors in a xenograft model [1][2] - The findings support further clinical exploration of nab-sirolimus as a single agent or in combination with other therapies [1][2] Group 1: Nonclinical Data Findings - Nab-sirolimus demonstrated significantly greater suppression of tumor growth in A549 xenografts compared to IV temsirolimus and oral sirolimus and everolimus [2] - Average intratumoral drug concentrations 24 hours after IV mTOR inhibitor treatment were 420-539 ng/g for nab-sirolimus, compared to 34.9 ng/g for temsirolimus and 13.2 ng/g for its active metabolite [2] - Tumor uptake of nab-sirolimus greatly exceeded that of sirolimus and everolimus at steady-state [2] Group 2: Clinical Trials and Future Directions - Aadi will present a trials-in-progress poster on its Phase 2 trial in advanced or recurrent endometrioid-type endometrial cancer (EEC), which is a difficult-to-treat mTOR-driven cancer [3] - The Phase 2 study aims to evaluate the efficacy and safety of nab-sirolimus in combination with letrozole for patients with advanced or recurrent EEC [3][4] - Dysregulation of mTOR signaling is implicated in over 80% of EEC cases, which harbor PTEN or PI3K/AKT/mTOR pathway alterations [3] Group 3: Company Overview - Aadi Bioscience focuses on developing and commercializing therapies for cancers with alterations in the mTOR pathway [5] - The company combines nanoparticle albumin-bound (nab) technology with sirolimus to enhance drug delivery, stability, solubility, and targeting [2][5] - Aadi has received FDA approval for FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa) [5]
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting